$HUM (Humana Inc.)

$HUM {{ '2016-10-12T19:28:06+0000' | timeago}} • Announcement

$HUM believes the decline in membership in 4-Star rated plans is primarily attributable to the impact of lower scores for certain Stars measures due to its recently-closed program audit by CMS. $HUM believes its Star ratings for the 2018 bonus year do not accurately reflect its actual performance under the applicable Star measures.

$HUM {{ '2017-07-12T13:21:50+0000' | timeago}} • Announcement

$HUM and Oscar Health are launching a strategic partnership to offer commercial health insurance to small businesses in a nine-county Nashville, Tenn. area.

$HUM {{ '2017-06-23T14:50:33+0000' | timeago}} • Announcement

$HUM has named Sam Deshpande to the newly created position of SVP and Chief Risk Officer. Mr. Deshpande will report directly to President and CEO Bruce Broussard. He comes to $HUM from Capital One.

$HUM {{ '2017-05-03T14:48:46+0000' | timeago}} • Webcast

$HUM said that it is selectively looking at group Medicare Advantage plan opportunities. The company has a team working on this and is confident on making adequate return on capital. There is no additional investment for group MA product in 2017. Humana depends on the competitive landscape and its relative market position.

$HUM {{ '2017-05-03T13:49:15+0000' | timeago}} • Announcement

As Humana posted 1Q17 results, $HUM reaffirmed its recent guidance for FY17 EPS guidance of at least $16.91. Total revenues are seen at $53.5-54.5Bil, with a capex of $550-600MM and cash flows from operations of $2.8-3.2Bil for the year.

$HUM {{ '2017-05-03T13:43:27+0000' | timeago}} • Announcement

Net revenue at $HUM slipped 0.3% to $13.8Bil in 1Q17, as its net income jumped more than four times to $1.1Bil from last year's $254MM. Earnings rose to $7.49 per diluted share from $1.68 a share, as Humana saw $947MM in merger termination gains for the quarter.

$AET {{ '2017-05-02T10:25:16+0000' | timeago}} • Announcement

$AET slipped to a loss in 1Q17 from a profit last year, due to costs associated with the termination of $HUM merger agreement. Net loss was $381MM or $1.11 per share compared to a profit of $737MM or $2.08 per share last year. Revenue declined 3% to $15.17Bil. Adjusted EPS increased to $2.71 from $2.32.

$HUM {{ '2017-04-20T13:17:09+0000' | timeago}} • Announcement

$HUM's BoD declared a quarterly cash dividend of $0.40 per share. The dividend is payable on July 31, 2017 to stockholders of record as of June 30, 2017.

$HUM {{ '2017-04-18T11:51:55+0000' | timeago}} • Announcement

$HUM realigned certain of its businesses for its financial reporting segments to correspond with internal management reporting changes and its planned exit from the individual commercial medical business on Jan. 1, 2018. The company’s segments now include Retail, Group and Specialty, Healthcare Services, and Individual Commercial.

$HUM {{ '2017-03-17T10:53:21+0000' | timeago}} • Announcement

$HUM completed its public offering of $1.0Bil in senior notes. These senior notes are comprised of $600MM 3.95% notes and $400MM 4.8% notes. Humana expects the net proceeds of approximately $988MM after expenses, to be used for general corporate purposes.

$HUM {{ '2017-02-14T15:19:12+0000' | timeago}} • Announcement

$HUM announced the mutual termination of the merger agreement with $AET. Under the terms of the merger agreement, $HUM is entitled to a breakup fee of $1Bil, or approx $630MM, net of tax.

$HUM {{ '2017-02-08T12:15:40+0000' | timeago}} • Announcement

$HUM said James Murray, EVP and COO, has decided to retire from that position effective March 31, 2017, and has agreed to serve as an advisor to the company through the end of the year. At this time, $HUM does not anticipate filling the COO role.

$HUM {{ '2017-02-08T12:14:06+0000' | timeago}} • Announcement

Following the Jan. 23, 2017 decision from the U.S. District Court of Columbia regarding $HUM's pending transaction with $AET, $HUM now expects to provide its 2017 financial guidance and hold a call to discuss that forecast and provide an update on the transaction with $AET no later than Feb. 16, 2017.

$HUM {{ '2017-02-08T12:10:43+0000' | timeago}} • Announcement

$HUM posted 4Q16 net loss of $401MM or $2.68 per share compared to a profit of $101MM or $0.67 per share last year. Revenue fell 3.6% to $12.88Bil, due to lower premiums from write-off of risk corridor receivables, loss of premiums from large group Medicare account and lower premium revenue from fewer Individual Commercial members.

$HUM {{ '2017-02-08T11:57:55+0000' | timeago}} • Announcement

$HUM slipped to a 4Q16 loss from a profit last year. This was due to write-off of about $583MM in receivables from risk corridor premium stabilization program as well as reserve strengthening for non-strategic closed block of long-term insurance business of $505MM.

$AET {{ '2017-01-31T19:56:54+0000' | timeago}} • Webcast

$AET did not repurchase shares during 2016 due to the pending $HUM acquisition. For 2017, operating EPS is projected to be at least $8.55 and operating revenue is expected to be $60-61Bil. This guidance represents a standalone scenario assuming there is no $HUM transaction. For 1Q17, membership is estimated to be 22.2-22.3MM medical members.

$AET {{ '2017-01-31T19:37:22+0000' | timeago}} • Webcast

$AET, whose merger with $HUM was blocked recently by the U.S. court, said that it is disappointed with the court's decision. $AET is conducting a thorough review of the court's opinion and considering options for responding to this ruling, including an appeal. The company expects to complete the review prior to the end date of the merger agreement.

$AET {{ '2017-01-31T11:29:11+0000' | timeago}} • Announcement

CEO Mark Bertolini said he has great deal of confidence in $AET's future, including its long-term prospects for growth. As considering next steps in proposed acquisition of $HUM, $AET remains focused on core strategy to deliver innovative, consumer-centric solutions that improve quality, affordability and the overall member experience.

$HUM {{ '2016-12-09T12:05:51+0000' | timeago}} • Announcement

$HUM lowered its FY16 GAAP EPS guidance to about $6.09 from about $8.68. The company still expects non-GAAP EPS of about $9.50. The company expects to exclude the impact of the risk corridor receivables write-off from its adjusted EPS for 4Q16 and FY16.

$HUM {{ '2016-12-09T12:03:47+0000' | timeago}} • Announcement

$HUM said a change in interpretation of the Affordable Care Act (ACA) associated with a recent court decision now requires the company to write-off essentially all of $591MM in receivables associated with risk corridor premium stabilization program outstanding as of Sept. 30, 2016.

$HUM {{ '2016-11-08T11:54:58+0000' | timeago}} • Announcement

$HUM said it is teaming up with MDLIVE, a telemedicine services and software provider. This is to provide Humana Medicare beneficiaries virtual access to doctors in select counties in Georgia and South Carolina.

Recent Transcripts

ANTM (Anthem, Inc.)
Wednesday, July 26 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
DGX (Quest Diagnostics Inc.)
Tuesday, July 25 2017 - 12:30pm
CNC (Centene Corp.)
Tuesday, July 25 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
GOOGL (Alphabet Inc.)
Monday, July 24 2017 - 9:00pm
MSFT (Microsoft Corporation)
Thursday, July 20 2017 - 9:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, July 18 2017 - 12:45pm
ENZ (Enzo Biochem Inc.)
Friday, June 9 2017 - 12:30pm
PDCO (Patterson Companies, Inc.)
Thursday, May 25 2017 - 2:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AIQ (Alliance Healthcare Services, Inc.)
Tuesday, May 9 2017 - 9:00pm
MOH (Molina Healthcare, Inc.)
Thursday, May 4 2017 - 9:00pm
AMED (Amedisys Inc.)
Wednesday, May 3 2017 - 3:00pm
HUM (Humana Inc.)
Wednesday, May 3 2017 - 1:00pm

AlphaGraphics you may like